Ovarian Cancer- Pipeline Insight, 2023

Ovarian Cancer- Pipeline Insight, 2023

DelveInsight’s, “Ovarian Cancer- Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Ovarian Cancer: Understanding

Ovarian Cancer: Overview

Ovarian Cancer is a type of cancer that begins in a woman’s ovaries – the small organs in the female reproductive system that create eggs. This kind of cancer can be difficult to detect because it often doesn’t cause any symptoms until later stages. Once found, Ovarian Cancer can be treated with chemotherapy and surgery to remove any tumors. As with most cancers, Ovarian Cancer becomes more common as a person gets older. The risk of Ovarian Cancer increases steeply from around 45 years and is greatest in those aged between 75 and 79 years. Between 5 and 15 out of 100 Ovarian Cancers (5 to 15%) are caused by an inherited faulty gene. Inherited genes that increase the risk of Ovarian Cancer include faulty versions of BRCA1 and BRCA2. Faults in these genes also increase the risk of breast cancer.

""Ovarian Cancer- Pipeline Insight, 2023"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ovarian Cancer pipeline landscape is provided which includes the disease overview and Ovarian Cancer treatment guidelines. The assessment part of the report embraces, in depth Ovarian Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ovarian Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ovarian Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Ovarian Cancer.

Ovarian Cancer Emerging Drugs Chapters

This segment of the Ovarian Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ovarian Cancer Emerging Drugs

Atezolizumab: Genentech

Atezolizumab is a humanized kappa immunoglobulin (Ig) G1 monoclonal antibody consisting of two heavy chains (448 amino acids) and two light chains (214 amino acids) and is produced in Chinese hamster ovary cells. Atezolizumab was engineered to eliminate Fc-effector function via a single amino acid substitution (asparagine to alanine) at position 298 on the heavy chain, which results in a non-glycosylated antibody that has minimal binding to Fc receptors and, consequently, eliminates detectable Fc-effector function and depletion of cells expressing programmed death−ligand 1 (PD-L1) in humans. Atezolizumab targets human PD-L1 and inhibits its interaction with its receptors, programmed death−1 (PD-1) and B7.1, both of which can provide inhibitory signals to T cells. The drug is currently in phase 3 of clinical trials for the treatment of Ovarian Cancer.

Tisotumab Vedotin: Genmab

Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis. Tisotumab vedotin includes an antibody targeting TF conjugated with monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. The drug is currently in phase 2 of clinical trials for the treatment of Ovarian Cancer.

Pembrolizumab: Merck

Keytruda (pembrolizumab) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.

Further product details are provided in the report……..

Ovarian Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Ovarian Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ovarian Cancer

There are approx. 100+ key companies which are developing the therapies for Ovarian Cancer. The companies which have their Ovarian Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.

Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Subcutaneous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibody

Small molecule

Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ovarian Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ovarian Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ovarian Cancer drugs.

Ovarian Cancer Report Insights

Ovarian Cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Ovarian Cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Ovarian Cancer drugs?

How many Ovarian Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ovarian Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ovarian Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Ovarian Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

IMV

Elucida Oncology

Chia Tai Tianqing Pharmaceutical Group

Precigen, Inc

Glycotope GmbH

Sonnet Biotherapeutics

Allarity Therapeutics

Adimab/Mersana Therapeutics

Genentech

Genmab

Merck

OncoQuest

IMPACT Therapeutics

Key Products

Maveropepimut S

ELU 001

TQ B3525

PRGN-3005 UltraCAR-T cells

PankoMab-GEX

SON 1010

Stenoparib

Upifitamab rilsodotin

Atezolizumab

Tisotumab Vedotin

Pembrolizumab

Oregovomab

Senaparib